News & Media

The Board of Directors of STAR7 S.p.A. discloses that the program has been early terminated, prior to the expiry of 5 April 2026, following the signing of the agreement to transfer control to Argos Fund.
 

The Board of Directors of STAR7 S.p.A. announces that it has been informed by the relevant shareholders Dante S.r.l. and STAR AG that, on today’s date, they entered into an agreement with Argos Fund.

Strong cash generation and reduction of net financial debt continue in 2025. Significant increase in Adjusted EBITDA Margin (16.7% vs. 15.7% in 2024).

The Board of Directors of STAR7 discloses that during the period between 01/02/2026 and 28/02/2026, it purchased 1,350 treasury shares at a volume-weighted average price of 8.4463 euro per share, for a total value of 11,402.50 euro.

The Board of Directors of STAR7 discloses that during the period between 01/01/2026 and 31/01/2026, it purchased 5,700 treasury shares at a volume-weighted average price of 8.54649 euro per share, for a total value of 48,714.99 euro.

STAR7 has published its financial calendar for 2026 in accordance with regulatory requirements.

The Board of Directors of STAR7 discloses that during the period between 01/12/2025 and 31/12/2025, it purchased 6,200 treasury shares at a volume-weighted average price of 8.21666 euro per share, for a total value of 50,943.30 euro.

The Board of Directors of STAR7 discloses that during the period between 01/11/2025 and 30/11/2025, it purchased 4,118 treasury shares at a volume-weighted average price of 8.26559 euro per share, for a total value of 34,037.72 euro.

STAR7 has announced the signing of an agreement for the acquisition of 20% of the share capital of Almon Inc. by its U.S. subsidiary STAR7 LLC.